KPTI Stock Analysis: Buy, Sell, or Hold?
KPTI - Karyopharm Therapeutics Inc.
$10.01
-0.04 (-0.40%)
▼
5d:
-0.4%
30d:
+11.22%
90d:
+20.89%
BUY
HIGH Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 10, 2026
26d
Get Alerted When KPTI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called KPTI this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: KPTI shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: KPTI shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: KPTI is currently trading at $10.01, which is considered slightly high relative to its 30-day fair value range of $9.02 to $10.09.
Technical Outlook: Technically, KPTI is in a uptrend. The price is approaching resistance at $9.98. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KPTI has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (18th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.50 (+34.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KPTI is in a uptrend. The price is approaching resistance at $9.98. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KPTI has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (18th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.50 (+34.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$9.02 -
$10.09
Company Quality Score
58/100
(HOLD)
Options IV Signal
18th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- BULLISH: Options cheap (IV 18th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 34.3% below Wall St target ($13.50)
Trading Range Analysis
30-Day Trading Range
$9.02 -
$10.09
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$1.73
(17.3%)
Support & Resistance Levels
Support Level
$8.43
Resistance Level
$9.98
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.06
Wall Street Target
$13.50
(+34.3%)
Revenue Growth (YoY)
16.8%
Profit Margin
-129.0%
Share & Embed Analysis
Last updated: July 14, 2026 4:54 PM ET
Data refreshes hourly during market hours. Next update: 5:54 PM
Data refreshes hourly during market hours. Next update: 5:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KPTI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Reshma Rangwala
SELL
449 shares
2026-04-21
Kristin Abate
SELL
50 shares
2026-01-28
Kristin Abate
SELL
265 shares
2026-01-21
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 58 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 51 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 60 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 62 BUY |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
12 analysts |
$20 | 63 BUY |
